Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The fact that PMCB may have the only treatment for the following...
"Two additional clinical trials will be conducted in the U.S. by Translational Drug Development (TD2). These trials will determine the effectiveness of PharmaCyte Biotech’s treatment in (i) reducing the severe pain that occurs in patients with advanced pancreatic cancer; and (ii) slowing the accumulation of malignant fluid (ascites) that accompanies the development of pancreatic and other solid cancerous tumors in the abdomen."
And...
"The study ... was designed by pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2."
...pretty significant facts, not opinions. This is why the growing interest in PMCB. This is being reported every where. The word is out.
http://www.pharmacytebiotech.com/pharmacyte-biotech-on-track-to-commence-clinical-trials/
http://www.pharmacytebiotech.com/pharmacyte-biotech-initiates-expanded-follow-study-united-states-accumulation-malignant-ascites-fluid/
Efood, a while back I talked about how a good friend taught me that everything is a process. I think the "word of mouth" process has gotten some legs and is beginning to run. As Ken Waggoner said, we "firmly believe our novel Cell-in-a-Box-based treatment will become a household name in the future."
http://www.pharmacytebiotech.com/pharmacyte-biotech-provides-update-on-corporate-developments-and-progress-with-cancer-and-diabetes-programs/
Yep, Bio, I totally see all that buying!!!
Great post! CiaB has always proven to be undeniable, imo. Now we have Dr Von Hoff to help us prove it to the world. Exciting times....
http://www.prnewswire.com/news-releases/clinical-milestones-abound-for-pharmacyte-biotech-in-2015-300057455.html
Appears to be matched by buyers. This is unusual for PMCB of late, imo. It is nice to see a buy for almost every sell. I think investors may be starting to outnumber traders. Nice...
Several different articles today from several different sources regarding PharmaCyte Biotech. The attention Cell in a Box(R) technology is getting is evident in our growing support.
Very good news for us longs who have been patiently waiting for the potential of this technology to be realized...
http://www.microcapdaily.com/pharmacyte-biotech-inc-otcmktspmcb-takes-center-stage/19944/
http://www.otcjournal.com/50-Breakout-Gain-For-Pharmacyte-PMCB-Have-You-Noticed/af/archive/20150401-1/
http://www.goldmanresearch.com/20150401957/Opportunity-Research/flurry-of-biotech-mergers-and-acquisitions-bodes-well-for-pharmacyte-biotech.html
http://www.pharmpro.com/news/2015/04/analyst-biotech-m-arms-race
Dr Von Hoff will see this gets to patients. He has the means and he has the will...
Never underestimate the power of compassion. If he can save the many patients he knows and others from pain and lost hope, he will.
If you read the comments, he did not even know Lincoln Capital was out of the picture. I don't take his opinion as a balanced view. I see it as uninformed. He repeated what we already know and from my perspective, only added that he was skeptical about up coming 3Q trials.
However, no matter how skeptical some may be, I think many are holding for expanded study results with the esteemed Dr Von Hoff.
I, you, and other longs, know why. Soon, everyone will know why. Plain and simple - Cell in a Box(R) technology and how it can change the medical world with more effective life changing treatments.
http://globenewswire.com/news-release/2015/03/16/715481/10124852/en/PharmaCyte-Biotech-Provides-Update-on-Corporate-Developments-and-Progress-With-Cancer-and-Diabetes-Programs.html
http://www.sigmaaldrich.com/technical-documents/articles/biology/cell-in-a-box.html
http://www.mdpi.com/1999-4923/6/3/447
Thanks for that pennyvestor. These articles are usually timed to encourage sell-off when we are trying to take-off. At least that has been my observation. I think the best news is that the article had little to no impact since we are still green today.
I really believe there is strong support here. In fact, the word is truly spreading. We will soon be unstoppable in my opinion...
CBS local news coverage of today's article regarding PMCB milestones.
http://www.wkrg.com/story/28646937/clinical-milestones-abound-for-pharmacyte-biotech-in-2015
Sounds like we have folks holding for results instead of the usual flipping for minimal gains. I think we may have some new investors as a result of last weeks volume, not the usual sell off.
Love you chart summary. Thanks
Good to hear from you Kano. It has been a while.
"These landmark preclinical trials for abdominal cancers using the Company's platform technology were designed, in part, by the leading authority on pancreatic cancer, Dr. Daniel Von Hoff, and conducted by America's leading Contract Research Organization that specializes in preclinical and early-mid phase clinical trials in oncology. Having such distinguished authorities associated with these trials affirms the potential value and efficacy of the Company's technology and could result in future, fast-tracked clinical trials."
I appreciate your thoughtful words. I can also understand your skeptism based on your past experiences.
That is why it is so important to your own DD and not rely on the advise of others. I am so confident in this technology and the people involved. That is why I am long here.
Best to you as well.
This historical data is what drew me to Cell in a Box(R) technology and the current studies for pain associated with pancreatic cancer and malignant ascites mentioned here is what keeps me patiently waiting.
The possibilies for CiaB to revolutionize medicine are right before us, imo...
Straight from that JNCI article...
"Another approach aims to make pancreatic cancer an operable disease. Using “Cell in a Box” technology developed by Austrianova, in Singapore, this cell therapy delivers ifosfamide locally to the cancer. Ifosfamide has previously shown promise as a chemotherapy against pancreatic cancer, but its effective dose was too toxic to give patients systemically. Instead, in the “Cell in the Box” approach, patients receive one-third of the usual dose of ifosfamide. “Cell in a Box” contains genetically modified cells that express the drug-metabolizing cytochrome P450 and converts the ifosfamide to its active form at the site of the tumor, according to CEO Brian Salmons, Ph.D. A catheter delivers the “Cell in a Box” capsule containing these cells to capillaries feeding the pancreas. This system of local delivery and activation greatly reduces side effects.
The European Medicines Agency fast-tracked this treatment, which is licensed to Nuvilex (Silver Spring, Md.). Nuvilex plans at least two new trials based on earlier phase I/II and phase II trials with a total of 27 patients with advanced pancreatic cancer. In the first, patients received two courses of ifosfamide at one-third the regular dose plus a urological protectant after transplantation of 300 capsules. Median survival after diagnosis rose to 40 weeks, compared with historical control of 28 weeks with gemcitabine, and 1-year survival increased to 36%, compared with 18% for gemcitabine. Four patients also reported improved pain, six were unchanged, and three had slightly more pain (The Lancet, May 19, 2001). However, in a second trial doubling the dosof ifosfamide, patients did not tolerate the drug well. Median survival was only 33 weeks, and 1-year survival was only 23%, suggesting that the lower dose previously used was better (Pharmaceutics, August 15, 2014, online).
“However, nine of the 27 patients were alive after 1 year, and two of these nine patients were alive for 2 years or more,” Salmons said.
An Australian phase IIb trial will test for median survival time and 1-year survival in advanced disease compared with best current treatment, and researchers plan a phase I/II trial for ascites (fluid in the abdomen) in metastatic cancer."
I am really interested to hear about the clinical studies and why they are doing two different trials. It appears the first will address just pain associated with pancreatic cancer and is most likely why we applied with the FDA for ODD for pancreatc cancer only.
The second will address malignant ascites which will aid all abdominal cancers. This second study is also for a treatment that no one else has. There is no other treatment for malignant ascites.
Interesting and thanks for making DD easier for investors by providing all your great posts.
Very nice summary of this weeks trading...
Thanks Bill
Yes, it is always good to hear from you bull...
That is such a great point. I guess trading is income for day traders that they use to pay the bills. That is the only reason that makes sense to me to not wait for a bigger pay off.
The volume was good. Probably some profit takers today but good to see a lot of interest especially for a Friday...
Additionally, this is important to note as well...
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside. Goldman Small Cap Research was compensated by a third party in the amount of $4000 for a research subscription service. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
I like the idea of selling a few at $30 Marlee. To good times, good health and a prosperous life for all stakeholders!
That depends on how long you are willing to wait. I think we have more potential value than Celgene does right now and we have already beat their Gold Standard. I think when our other uses hit market, we are talking $100+ but that is a long way off. I plan on holding for the long long term. I have mine in a Roth.
Maybe the word is out and pictures are being shared on Twitter. Instiling investor confidence for sure. :)
I am still more interested in what is happening in Scottsdale.
It sure looks that way to me. I am not surprised. I don't think it's just the Goldman article. I wonder if some are hearing about the study results.
With good results on the first study, I am thinking the expanded study is wrapping up with good results as well. I see this technology revolutionizing the way many medicinals are delivered.
"Those who have ears to hear, let them hear."
This is a very good opportunity for us little retail investors.
GLTA
Good deal, Pete. That sounds better for you. Scotty will not let me do that and I would only put in a number I would be happy to sell at if I could.
You have a lot of shares and at $10 a share, you would be sitting very well on your investment.
I can't do it Pete. What if it jumps that high before I get a chance to take it off? Today proved to me that traders and shorts are no longer steering this helm. And I am looking for a bigger pay off than $5. This technology is worth way more than that, imo.
I think some big ballers are in now. Tomorrow will definitely give us more indication but my guess is, the word is out and trial results may have been very good.
Yesterday I posted this...
I don't know how accurate ihubs trades page is but if the buys are correct, we are looking at some possible new players in the game. Just hoping they are in it for the long haul...
1.9m buys vs 900k sells.
Today, the trades are not showing. I wonder why? Makes me think it is not showing because someone doesn't want us to see the buying action.... Interesting.
I can see trades for every other company.
Moi aussi, bien sur!
I wouldn't sell a share either at $1.80. I don't own as many shares as most but I have always, it's not how many you own, it's how many you hold. I am holding for a much bigger payout. :)
I think there are plenty in the wings waiting to buy. No worries, there is always someone who wants in on a good thing. Those shares will be picked right up. I know someone right now trying to buy 100k shares and only 50k filled so far. You may have just done him a solid.
Good luck to you Luco.
Nice...
Seven Reasons Why We Believe PMCB is a Four Bagger
PMCB owns exclusive rights to a technology that could emerge as the first universal therapy and treatment of choice for multiple cancers and diabetes, potentially worth billions in annual sales down the road.
Favorable legacy and updated results from early-mid-stage pancreatic cancer clinical trials will be followed by the commencement of a Phase 2b clinical trial in 2H15.
The high profile and coveted Orphan Drug designation was granted by the FDA in December, 2014 to PMCB’s pancreatic cancer treatment.
Preclinical trials for abdominal cancers using the Company’s platform technology were designed, in part, by the leading authority on pancreatic cancer, Dr. Daniel Von Hoff, and conducted by America’s leading Contract Research Organization that specializes in oncology. This substantially raises the PMCB profile and could result in future, fast-tracked trials.
A series of steps are in progress that will lead toward diabetes clinical trials, which, in turn, represent a substantial market opportunity.
Management is actively engaged in pursuing the use of compounds from the Cannabis plant (known as “cannabinoids”) in combination with its Cell-in-a-Box® platform technology to treat deadly cancers where there are no substantially effective treatments on the market.
With multiple shots on goal we believe that PMCB’s stock is overlooked and grossly undervalued, relative to its peer group, as outlined in our report.
Those who have ears to hear, let them hear...
http://www.goldmanresearch.com/20150326950/Opportunity-Research/pmcb-is-a-four-bagger.html
What the heck! We are over .13 now? Volume 4M+ already? Just now getting here today and the word of this amazing technology seems to be spreading like wildfire!
I agree wholeheartedly bill and I will share this again. Those who have ears to hear, let them hear. All others may be missing a great opportunity to be part of something pretty amazing. Btw, this article has been posted on Dr Von Hoff's and team's website for a year... PMCB, formerly Nuvilex...
"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."
The tool, Cell in a Box(R) technology.
http://www.td2inc.com/news/nuvilex-selects-translational-drug-development-td2-to-advanc
We had a few new posters saying they bought in today and are holding. Very nice... :)
We don't need him to mention Cell in a Box(R) on Friday and it is very likely he won't. Wouldn't want to steal someone else's thunder, pun intended. Lol
Nonetheless, we will get results from the current study at some point over the next few months. It looks like the word is out about Cell in a Box(R) and if that is true, with documented results, this just may fly...
I know many are skeptical and I hope for the sake of those who are and just sitting on the sidelines, that something will help you realize the value of treating pain and ascites for patients with all abdominal cancers before this price may be out of reach for many.
Personally, I think they had to do an expanded studt because the first study's results were so amazing.
I could be wrong but Dr Von Hoff is still on board and planning a Phase 1 with Cell in a Box(R) technology. I have many reasons for standing strong. His studies just happen to be the most significant with impending potentially mind blowing results.
Just think, if it helps reduce pain, we go from inoperable to operable and the patient's quality of life were to improve, how amazing to be a part of that.
Nothing will move me from supporting CiaB in every way I can.
I wish you the best in your endeavors as well...